单位：[1]Institute of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China[2]The Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei 230032, China[3]Collaborative Innovation Center for Complex and Severe Dermatosis, Anhui Medical University, Hefei 230032, China[4]Department of Dermatology, China-Japan Friendship Hospital, Beijing 100029, China[5]Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China[6]Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China[7]Molecular and Integrative Physiological Sciences, Harvard T.H. CHAN School of Public Health, Boston, MA 02115, USA[8]Hebrew SeniorLife Institute for Aging Research and Harvard Medical School, Boston, MA 02131, USA[9]Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA[10]Department of Dermatology, The Second Affiliated Hospital, Anhui Medical University, Hefei 230601, China[11]Department of Biochemistry, University of New Mexico, Albuquerque, NM 87131, USA
Psoriasis (Ps) is an inflammatory skin disease caused by genetic and environmental factors. Previous studies on DNA methylation (DNAm) found genetic markers that are closely associated with Ps, and evidence has shown that DNAm mediates genetic risk in Ps. In this study, Consensus Clustering was used to analyze DNAm data, and 114 Ps patients were divided into three subclassifications. Investigation of the clinical characteristics and copy number variations (CNVs) of DEFB4, IL22, and LCE3C in the three subclassifications revealed no significant differences in gender ratio and in Ps area and severity index (PASI) score. The proportion of late-onset ( 40 years) Ps patients was significantly higher in type I than in types II and III (P = 0.035). Type III contained the smallest proportion of smokers and the largest proportion of non-smoking Ps patients (P = 0.086). The CNVs of DEFB4 and LCE3C showed no significant differences but the CNV of IL22 significantly differed among the three subclassifications (P = 0.044). This study is the first to profile Ps subclassifications based on DNAm data in the Chinese Han population. These results are useful in the treatment and management of Ps from the molecular and genetic perspectives.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81502713]; Grants for Scientific Research of BSKY from Anhui Medical University [XJ201634]; Key Program of Outstanding Talents of Anhui Province [gxyqZD2017028]
第一作者单位：[1]Institute of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China[2]The Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei 230032, China[3]Collaborative Innovation Center for Complex and Severe Dermatosis, Anhui Medical University, Hefei 230032, China
共同第一作者：
通讯作者：
通讯机构：[1]Institute of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China[2]The Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei 230032, China[3]Collaborative Innovation Center for Complex and Severe Dermatosis, Anhui Medical University, Hefei 230032, China[6]Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China[10]Department of Dermatology, The Second Affiliated Hospital, Anhui Medical University, Hefei 230601, China
推荐引用方式(GB/T 7714)：
Fusheng Zhou,Changbing Shen,Yi-Hsiang Hsu,et al.DNA methylation-based subclassification of psoriasis in the Chinese Han population[J].FRONTIERS of MEDICINE.2018,12(6):717-725.doi:10.1007/s11684-017-0588-6.
APA：
Fusheng Zhou,Changbing Shen,Yi-Hsiang Hsu,Jing Gao,Jinfa Dou...&Xuejun Zhang.(2018).DNA methylation-based subclassification of psoriasis in the Chinese Han population.FRONTIERS of MEDICINE,12,(6)
MLA：
Fusheng Zhou,et al."DNA methylation-based subclassification of psoriasis in the Chinese Han population".FRONTIERS of MEDICINE 12..6(2018):717-725
